Form 4: Stoke Therapeutics Chief Medical Officer Sells Over 4,500 Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 4,503 shares of common stock for approximately $52,370 through a pre-established Rule 10b5-1 trading plan.
Summary
- Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported the sale of 4,503 shares of common stock.
- The transaction occurred on July 1, 2025, at a weighted average price of $11.6321 per share.
- The total value of the shares sold was approximately $52,370.46.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ticho on December 11, 2024.
- Following this transaction, Mr. Ticho beneficially owns 21,279 shares of Stoke Therapeutics common stock directly.
- The shares were sold in multiple transactions within a price range of $11.31 to $11.99 per share.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an insider sale can be seen negatively, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic selling, indicating a planned financial management action rather than a reaction to negative company news.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an opportunistic sale, which enhances transparency and reduces concerns about insider timing.
Negatives
- An insider selling shares, even if pre-planned, can sometimes be perceived as a slight negative signal regarding future prospects, although this is mitigated by the 10b5-1 plan.
- The transaction reduces the direct beneficial ownership of a key executive in the company.
Risks
- No specific risks are detailed in this Form 4 filing beyond the general informational nature of an insider stock sale.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This insider transaction is specific to Stoke Therapeutics and does not directly reflect broader industry trends. It is a routine disclosure for publicly traded companies regarding executive stock ownership changes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compliance Mechanism | The transaction was conducted under a Rule 10b5-1 trading plan, which is a pre-arranged plan designed to allow insiders to sell shares without being accused of trading on material non-public information. This reflects adherence to SEC regulations regarding insider trading. | 12/11/2024 | Enhances corporate governance by demonstrating a commitment to transparent and compliant insider trading practices, reducing potential legal and reputational risks associated with insider transactions. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in the Chief Medical Officer's direct ownership, which is publicly disclosed for transparency.
- Employees: No direct impact on employees is indicated by this filing.
- Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 12/11/2024 | Date the Rule 10b5-1 trading plan was adopted by Barry Ticho. |
| 07/01/2025 | Date of the reported transaction (sale of common stock). |
| 07/02/2025 | Date the Form 4 was signed and filed. |
Keywords
Stoke Therapeutics, STOK, Insider Trading, Stock Sale, SEC Form 4, Rule 10b5-1, Chief Medical Officer, Equity Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.